Ann: BTX 1503 Acne Phase 2 Study Results Presentation, page-423

Botanix Pharmaceuticals Limited (ASX: BOT) ​

Perth and Philadelphia based clinical stage synthetic cannabinoid company, Botanix Pharmaceuticals Limited (ASX: BOT) develops topical treatments for serious skin diseases that are safe as well as effective, taking advantage of the unique anti-inflammatory, immune modulating and antimicrobial properties of synthetic cannabidiol.


Botanix has an advanced dermatology pipeline as shown below.






BTX 1503 Acne Phase 2 Study Results



As announced on 22 October 2019, BOT’s securities were placed on a trading halt at the request of BOT, pending release of an announcement regarding BTX 1503 Acne Phase 2 Study Results. BOT resumed trading today on the release of the results, the snippet of which is given below-







Botanix is moving forward with its preparations for Phase 3 clinical program and planning an end-of-Phase 2 meeting with the US Food and Drug Administration
Cannabidiol supply agreement signed between Botanix and Purisys

• Dated 21 October 2019, Botanix notified the market on the Supply Agreement execution with the industry’s leading provider of ultra-pure, pharmaceutical grade cannabidiol technology, Purisys, covering the immediate expanding demand and future commercial supplies of synthetic cannabidiol active pharmaceutical ingredient (API).
• Under this agreement, Botanix and Purisys would also collaborate to set forthcoming bulk requirements as well to scale up and optimise the manufacturing process.
• The agreement is termed up till December 2027.

Grant for Botanix’ Synthetic Cannabidiol Analog Program

• In an announcement dated 15 October 2019, it has been notified that Botanix puts a feather in its hat by receiving a new Innovation Connections Grant award from the Federal Government’s Department of AusIndustry.
• This grant would fast-track Botanix’ medicinal chemistry program that targets the manufacturing of new synthetic analogs of cannabidiol, in addition to investigate further the mode of action of cannabidiol.
• To overcome the challenges of bioavailability of the natural molecule and to enhance the performance of cannabidiol, new analogs are being developed have a unique structure and activity profile that can be patented as novel chemical entities.
• Development of synthetic cannabidiol analogs is taking place with the support from scientists at The University of Queensland (UQ).

Stock Performance


On 23 October 2019, BOT’s shares are trading at $0.125, down by 47.9% (as at 03:25 PM AEST). The market capitalization of the company stands at $231.48 million with 964.5 million outstanding shares. BOT’s stock has generated an outstanding YTD return of 228.77% till date.